Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 12/20 | 0.47 |
| ▸ | ATF1 | P18846 | 11/20 | 0.47 |
| ▸ | XPO1 | O14980 | 4/20 | 0.46 |
| ▸ | JUN | P05412 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76465 | 0.86 | SCD (0.51) | SCDNFKB1ATF1XPO1JUN | |
| SCHEMBL541592 | 0.83 | NFKB1 (0.52) | SCDNFKB1ATF1XPO1JUN | |
| SCHEMBL541570 | 0.79 | SYK (0.43) | SCDALOX5APFEN1 | |
| SCHEMBL12796211 | 0.77 | CNR2 (0.59) | — | |
| SCHEMBL541310 | 0.77 | CNR2 (0.43) | NFKB1ATF1ALOX5APFEN1 | |
| SCHEMBL12796596 | 0.76 | CXCR4 (0.41) | SCDNFKB1JUNNFKB2RELA | |
| SCHEMBL12796600 | 0.76 | CXCR4 (0.41) | SCDNFKB1JUNNFKB2RELA | |
| SCHEMBL541983 | 0.76 | CXCR4 (0.39) | SCDNFKB1ATF1JUNNFKB2 | |
| SCHEMBL542021 | 0.75 | CXCR4 (0.38) | SCDNFKB1JUNNFKB2RELA | |
| SCHEMBL6521507 | 0.75 | HDAC3 (0.41) | SCDNFKB1JUNNFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| CN-102378757-A | Pyrimidine compounds | ASTELLAS PHARMA INC | 2012-03-14 | — | — | CN | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | SCD 1093/4885NFKB1 2708/4885ATF1 1914/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | SCD 1251/4885NFKB1 2619/4885ATF1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.